Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXS6837 Versus Eculizumab in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT07747090Phase 3Not yet recruiting
- Sponsor
- Fosun Pharma
- Start
- Dec 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 3 trial of FXS6837 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Fosun Pharma. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
FXS6837
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07747090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07747090.